198 related articles for article (PubMed ID: 23480183)
1. Anti-high mobility group box 1 monoclonal antibody ameliorates experimental autoimmune encephalomyelitis.
Uzawa A; Mori M; Taniguchi J; Masuda S; Muto M; Kuwabara S
Clin Exp Immunol; 2013 Apr; 172(1):37-43. PubMed ID: 23480183
[TBL] [Abstract][Full Text] [Related]
2. Recombinant thrombomodulin ameliorates experimental autoimmune encephalomyelitis by suppressing high mobility group box 1 and inflammatory cytokines.
Uzawa A; Mori M; Masuda H; Ohtani R; Uchida T; Kuwabara S
Clin Exp Immunol; 2018 Jul; 193(1):47-54. PubMed ID: 29509323
[TBL] [Abstract][Full Text] [Related]
3. High-mobility group box 1 protein (HMGB1) neutralization ameliorates experimental autoimmune encephalomyelitis.
Robinson AP; Caldis MW; Harp CT; Goings GE; Miller SD
J Autoimmun; 2013 Jun; 43():32-43. PubMed ID: 23514872
[TBL] [Abstract][Full Text] [Related]
4. Nobiletin attenuates inflammation via modulating proinflammatory and antiinflammatory cytokine expressions in an autoimmune encephalomyelitis mouse model.
Yarim GF; Yarim M; Sozmen M; Gokceoglu A; Ertekin A; Kabak YB; Karaca E
Fitoterapia; 2022 Jan; 156():105099. PubMed ID: 34896483
[TBL] [Abstract][Full Text] [Related]
5. HMGB1 expression patterns during the progression of experimental autoimmune encephalomyelitis.
Sun Y; Chen H; Dai J; Zou H; Gao M; Wu H; Ming B; Lai L; Xiao Y; Xiong P; Xu Y; Gong F; Zheng F
J Neuroimmunol; 2015 Mar; 280():29-35. PubMed ID: 25773152
[TBL] [Abstract][Full Text] [Related]
6. Treatment with a recombinant human IgM that recognizes PSA-NCAM preserves brain pathology in MOG-induced experimental autoimmune encephalomyelitis.
Lemus HN; Warrington AE; Denic A; Wootla B; Rodriguez M
Hum Antibodies; 2017; 25(3-4):121-129. PubMed ID: 28269761
[TBL] [Abstract][Full Text] [Related]
7. Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate.
Aharoni R; Vainshtein A; Stock A; Eilam R; From R; Shinder V; Arnon R
J Autoimmun; 2011 Nov; 37(3):228-41. PubMed ID: 21752599
[TBL] [Abstract][Full Text] [Related]
8. High-affinity σ1 protein agonist reduces clinical and pathological signs of experimental autoimmune encephalomyelitis.
Oxombre B; Lee-Chang C; Duhamel A; Toussaint M; Giroux M; Donnier-Maréchal M; Carato P; Lefranc D; Zéphir H; Prin L; Melnyk P; Vermersch P
Br J Pharmacol; 2015 Apr; 172(7):1769-82. PubMed ID: 25521311
[TBL] [Abstract][Full Text] [Related]
9. Treatment With CD52 Antibody Protects Neurons in Experimental Autoimmune Encephalomyelitis Mice During the Recovering Phase.
Hao W; Luo Q; Menger MD; Fassbender K; Liu Y
Front Immunol; 2021; 12():792465. PubMed ID: 34975892
[TBL] [Abstract][Full Text] [Related]
10. Obinutuzumab-Induced B Cell Depletion Reduces Spinal Cord Pathology in a CD20 Double Transgenic Mouse Model of Multiple Sclerosis.
Breakell T; Tacke S; Schropp V; Zetterberg H; Blennow K; Urich E; Kuerten S
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962135
[TBL] [Abstract][Full Text] [Related]
11. Transglutaminase 2 exacerbates experimental autoimmune encephalomyelitis through positive regulation of encephalitogenic T cell differentiation and inflammation.
Oh K; Park HB; Seo MW; Byoun OJ; Lee DS
Clin Immunol; 2012 Nov; 145(2):122-32. PubMed ID: 23001131
[TBL] [Abstract][Full Text] [Related]
12. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses.
Feng M; Shu Y; Yang Y; Zheng X; Li R; Wang Y; Dai Y; Qiu W; Lu Z; Hu X
Neurochem Int; 2014 Jan; 64():64-72. PubMed ID: 24274996
[TBL] [Abstract][Full Text] [Related]
13. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis.
Wen J; Ribeiro R; Tanaka M; Zhang Y
Neuropharmacology; 2015 Dec; 99():196-209. PubMed ID: 26189763
[TBL] [Abstract][Full Text] [Related]
14. Interleukin 2 Ameliorates Autoimmune Neuroinflammation by Modulating the Balance of T Helper 17 Cells and Regulatory T Cells in Mouse.
Li J; Zhang Z; Du S; Guo Q
Ann Clin Lab Sci; 2021 Jul; 51(4):529-534. PubMed ID: 34452891
[TBL] [Abstract][Full Text] [Related]
15. Ellagic acid protects from myelin-associated sphingolipid loss in experimental autoimmune encephalomyelitis.
Busto R; Serna J; Perianes-Cachero A; Quintana-Portillo R; García-Seisdedos D; Canfrán-Duque A; Paino CL; Lerma M; Casado ME; Martín-Hidalgo A; Arilla-Ferreiro E; Lasunción MA; Pastor Ó
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):958-967. PubMed ID: 29793057
[TBL] [Abstract][Full Text] [Related]
16. Butylphthalide ameliorates experimental autoimmune encephalomyelitis by suppressing PGAM5-induced necroptosis and inflammation in microglia.
Wang Y; Bi Y; Xia Z; Shi W; Li B; Li B; Chen L; Guo L
Biochem Biophys Res Commun; 2018 Feb; 497(1):80-86. PubMed ID: 29407174
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: down-regulation of inflammatory and autoimmune responses.
Gonzalez-Rey E; Fernandez-Martin A; Chorny A; Martin J; Pozo D; Ganea D; Delgado M
Am J Pathol; 2006 Apr; 168(4):1179-88. PubMed ID: 16565493
[TBL] [Abstract][Full Text] [Related]
18. IC100: a novel anti-ASC monoclonal antibody improves functional outcomes in an animal model of multiple sclerosis.
Desu HL; Plastini M; Illiano P; Bramlett HM; Dietrich WD; de Rivero Vaccari JP; Brambilla R; Keane RW
J Neuroinflammation; 2020 May; 17(1):143. PubMed ID: 32366256
[TBL] [Abstract][Full Text] [Related]
19. Efficient Distribution of a Novel Zirconium-89 Labeled Anti-cd20 Antibody Following Subcutaneous and Intravenous Administration in Control and Experimental Autoimmune Encephalomyelitis-Variant Mice.
Migotto MA; Mardon K; Orian J; Weckbecker G; Kneuer R; Bhalla R; Reutens DC
Front Immunol; 2019; 10():2437. PubMed ID: 31681317
[No Abstract] [Full Text] [Related]
20. Immunization with a peptide of Semliki Forest virus promotes remyelination in experimental autoimmune encephalomyelitis.
Mokhtarian F; Safavi F; Sarafraz-Yazdi E
Brain Res; 2012 Dec; 1488():92-103. PubMed ID: 23031637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
